For Q3 2026, the company expects NGS ARR in the range of $7.94 billion to $7.96 billion, revenue of $2.941 billion to $2.945 billion, and diluted non-GAAP EPS of $0.78 to $0.80. For the full fiscal ...
This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted ...
Impact of Fee For Service on the Efficiency and Survival of Seguro Popular's Patients With Acute Lymphoblastic Leukemia in Mexico We used a tiered testing pipeline of immunohistochemistry (IHC), ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results